Botanix Pharmaceuticals Limited · ASX:BOT
Botanix Pharmaceuticals — Investor Presentation (September 2021)
24 slides from Botanix Pharmaceuticals's investor presentation, Sep 1, 2021
Slide 1: Botanix Presentation Corporate Update
1 September 2021 Botanix Presentation Corporate Update Key highlights For personal use only • Botanix has released a corporate presentation being utilised for investor meetings • Presentation highlights the successful launch of BTX 1702 rosacea clinical study, with recruitment well underway • Presen
Slide 2: Contact and Cautionary Note on Forward-Looking Statements
For more information, please contact: General Investors Media Corporate Communications Joel Seah Haley Chartres Botanix Pharmaceuticals Vesparum Capital H^CK For personal use only Phone: +61 8 6555 2945 Phone: +61 3 8582 4800 Phone: +61 423 139 163 investors@botanixpharma.com botanixpharma@vesparum.
Slide 3: Investor Presentation September 2021
For personal use only Investor Presentation September 2021 www.botanixpharma.com
Slide 4: World-class team
World class team World-class team For personal use only Board of Directors Vince Ippolito Matt Callahan Dr Bill Bosch Dr Stewart Washer President and Executive Chairman Executive Director Executive Director Director v COO of Anacor and Medicis with 17 v Serial founder and ex-investment v 20+ years e
Slide 5: Botanix: a leader in topical drug development
Botanix: a leader in topical drug development For personal use only Pharmaceutical focus Leveraging novel skin delivery technology (Permetrex™) and novel drug mechanisms of action, including cannabidiol (CBD) Topically driven Targeting key dermatology and antimicrobial indications with topical treat
Slide 6: Corporate overview
Corporate Corporate overview For personal use only Trading information Share price performance (last 12 months) Share Price (31 August 2021) A$0.080 Price (A$) Volume (m) 52 week low / high A$0.045 / A$0.190 $0.20 90 Shares outstanding 973,142,074 80 Market capitalisation A$78.8 $0.16 70 Cash (30 Ju
Slide 7: Advanced pipeline
Pharmaceutical focus Advanced pipeline For personal use only Ph 1 Ph 1b Ph 2 Ph 3 Status Positive Phase 2a results 1Q BTX 1801 2021, Phase 2b planning Antimicrobial advanced BTX 1702 First patients enrolled end Rosacea 2Q 2021 BTX 1503 Planning underway for Phase 3 Acne clinical studies Actively ass
Slide 8: Significant markets
Significant markets Our products target markets with significant annual revenue For personal use only Antimicrobial Specialised / Rosacea 100k patients Dermatologists 16M patients $0.5bn sales2 $1.9bn sales1 US Prescriber Acne Base 50M patients $5.1bn sales3 General Practitioners Preclinical Phase 1
Slide 9: Permetrex: unique skin delivery technology fuels pipeline
Topically driven PermetrexTM: unique skin delivery technology fuels pipeline Delivers high doses of drug into the layers of the skin without using permeation enhancers, For personal use only preservatives, or irritating levels of alcohol / petroleum derivatives Initial application Evaporation of sol
Slide 10: Synthetic cannabinoids are well suited to treat skin diseases and infections
Pharmaceutical focused Synthetic cannabinoids are well suited to treat skin diseases and infections For personal use only Botanix’s studies show synthetic CBD to:1 ü Be safe and well tolerated ü Have broad anti-inflammatory properties ü Have a strong and consistent impact on lesions ü Kill Staph aur
Slide 11: BTX 1801 development update
BTX 1801 development update For personal use only
Slide 12: Antimicrobial resistance is a fast-growing problem
Antimicrobial Antimicrobial resistance is a fast-growing problem, with no innovation in over three decades For personal use only Global forecast deaths by 20501 (p.a.) Number of antibiotic classes discovered or patented2 10.0m 9 55+ year gap Without new innovative solutions, No new approved classes
Slide 13: BTX 1801 has remarkable activity against bacteria without inducing resistance
Antimicrobial BTX 1801 has remarkable activity against bacteria without inducing resistance For personal use only MIC daily variability1 12 26x fold increase from Day 1 8 An increase in MIC over time MIC (µg/mL) shows MRSA can develop resistance to the drug 4 1.5x fold increase from Day 1 - 1 2 3 4
Slide 14: BTX 1801 Phase 2a study: clinical efficacy demonstrated
Antimicrobial BTX 1801 Phase 2a study: clinical efficacy demonstrated For personal use only ü Safe and generally well tolerated at doses of active drug up to 20% ü All 66 participants successfully Safety & completed the BTX 1801 study tolerability ü No severe adverse events reported1 BTX 1801 BTX 18
Slide 15: Haemodialysis patients with central venous catheters at risk of bloodstream infections
Antimicrobial Haemodialysis patients with central venous catheters at risk of bloodstream infections For personal use only Haemodialysis v Replicates the functions of the kidneys in patients with kidney failure, by using a machine to filter and clean the blood v Infection is a leading cause of death
Slide 16: BTX 1801: rapid clinical development
Antimicrobial BTX 1801: rapid clinical development For personal use only FDA incentives provide accelerated Next Study Phase 1 Phase 2b development and increase exclusivity Safe and delivers Effective at killing Staph aureus synthetic cannabidiol over 2 months, with 2-3 times v Extra 5 years (total
Slide 17: Dermatology clinical programs
Dermatology clinical programs For personal use only
Slide 18: BTX 1702: impact of rosacea and significant market opportunity
Dermatology BTX 1702: impact of rosacea and significant market opportunity For personal use only v Papulopustular rosacea is a A rapidly growing market: chronic skin disease Rosacea market projected to grow to US$2.6bn by 20253 characterised by redness (inflammation) and acne- US$2.6bn Anticipated t
Slide 19: BTX 1702: Phase 1b rosacea study underway
Dermatology BTX 1702: Phase 1b rosacea study underway For personal use only Study design v Four dose groups, ~120 patients: v Endpoints: – BTX 1702 high dose - twice daily: 40 patients – Safety and tolerability – BTX 1702 low dose - twice daily: 40 patients – Change in inflammatory lesion counts fro
Slide 20: BTX 1204A dermatitis data
Dermatology BTX 1204A dermatitis data New animal data supports further development of indication For personal use only BTX 1204A: Pruritus mean ESP scores1,2 BTX 1204A: % reduction from baseline (CADESI-04)1,3 Extremely 0.0% 10 Baseline severe (10.0%) 8 Severe (20.0%) BT 6 Moderate X1 BTX 1 20 20 (3
Slide 21: BTX 1204A development strategy
Dermatology BTX 1204A development strategy: Larger POC canine study commencing - informs licensing program for animal use For personal use only and potential relaunch of late-stage dermatitis clinical program Proposed canine study parameters Planned pathway to approval v Three dose groups ~45 dogs:
Slide 22: BTX 1503 Acne: Successful End-of-Phase FDA Meeting and preparation for Phase 3
Dermatology BTX 1503 Acne: Successful End-of-Phase 2 FDA Meeting and preparation for Phase 3 For personal use only Study update Sizable acne prescription market ü End of Phase 2 meeting with FDA successfully completed ü FDA highlighted excellent safety profile of BTX 1503, and 22m total prescription
Slide 23: Executing on key clinical milestones
Corporate Executing on key clinical milestones For personal use only v Antimicrobial: positive BTX 1801 Phase 2a study results Positive results announced and Phase 2b planned start 4Q 2021 v Rosacea: BTX 1702 Phase 1b study enrolling Recruitment currently underway v Acne: BTX 1503 planning for Phase
Slide 24: Disclaimer
DISCLAIMER For personal use only Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate, ”expect,” “intend,” “may,” “plan,” “predict,”
Botanix Pharmaceuticals — Investor Presentation (September 2021) on 6ix